Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
01 mai 2020 10h17 HE
|
Delcath Systems, Inc.
NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the...
Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors
19 févr. 2020 08h30 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that...
Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma
13 janv. 2020 08h30 HE
|
Delcath Systems, Inc.
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today...
Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019
19 déc. 2019 08h30 HE
|
Delcath Systems, Inc.
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that...
Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019
03 déc. 2019 08h30 HE
|
Delcath Systems, Inc.
NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced...
Delcath Systems Announces Postponement of Reverse Stock Split
22 oct. 2019 07h27 HE
|
Delcath Systems, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Systems Announces Ratio for Reverse Stock Split
18 oct. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Systems to Present at the MicroCap Rodeo Investor Conference
08 oct. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will present at the MicroCap Rodeo. The conference will be held October...
Delcath Systems to Participate in Upcoming Investor Conferences
23 sept. 2019 11h30 HE
|
Delcath Systems, Inc.
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will participate at the following upcoming investor conferences in New...
Delcath Systems Announces Presentation at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright
28 août 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will present at the Rodman & Renshaw 21st Annual Global Investment...